- Home
- ABVC vs ALGS Comparison
ABVC vs ALGS Comparison
Compare ABVC & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- ALGS
- Stock Information
- Founded
- ABVC 2015
- ALGS 2018
- Country
- ABVC United States
- ALGS United States
- Employees
- ABVC N/A
- ALGS N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- ALGS Health Care
- Exchange
- ABVC Nasdaq
- ALGS Nasdaq
- Market Cap
- ABVC 52.1M
- ALGS 53.0M
- IPO Year
- ABVC N/A
- ALGS 2020
- Fundamental
- Price
- ABVC $3.30
- ALGS $7.70
- Analyst Decision
- ABVC
- ALGS Strong Buy
- Analyst Count
- ABVC 0
- ALGS 1
- Target Price
- ABVC N/A
- ALGS $70.00
- AVG Volume (30 Days)
- ABVC 223.6K
- ALGS 62.6K
- Earning Date
- ABVC 08-13-2025
- ALGS 08-06-2025
- Dividend Yield
- ABVC N/A
- ALGS N/A
- EPS Growth
- ABVC N/A
- ALGS N/A
- EPS
- ABVC N/A
- ALGS N/A
- Revenue
- ABVC $391,242.00
- ALGS $3,174,000.00
- Revenue This Year
- ABVC $735.18
- ALGS N/A
- Revenue Next Year
- ABVC N/A
- ALGS $51.55
- P/E Ratio
- ABVC N/A
- ALGS N/A
- Revenue Growth
- ABVC 186.84
- ALGS N/A
- 52 Week Low
- ABVC $0.40
- ALGS $3.76
- 52 Week High
- ABVC $5.48
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- ABVC 56.53
- ALGS 46.70
- Support Level
- ABVC $2.90
- ALGS $7.31
- Resistance Level
- ABVC $3.06
- ALGS $7.85
- Average True Range (ATR)
- ABVC 0.28
- ALGS 0.75
- MACD
- ABVC 0.00
- ALGS -0.09
- Stochastic Oscillator
- ABVC 91.92
- ALGS 35.03
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.